Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Search
Medicines Law & Policy
Research and resources on intellectual property and health
Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Tag: Gilead
Wrapping up 2020 with some noteworthy medicines, law and policy events
Medicines Law & Policy
-
December 29, 2020
Price, profit and the Covid-19 health technology pool: The example of...
Christopher Garrison
-
May 28, 2020
CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests
Pascale Boulet
-
September 10, 2018
The Power of TRIPS Flexibilities in Medicines Procurement
Ellen 't Hoen
-
April 9, 2018
Gilead’s sofosbuvir patent in India – options for global access to...
Ellen 't Hoen
-
May 26, 2016
This work is licensed under Creative Commons.